Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. China Shineway Pharmaceutical Group's cash to debt ratio for the quarter that ended in Dec. 2025 was 22.59.
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, China Shineway Pharmaceutical Groupcould pay off its debt using the cash in hand for the quarter that ended in Dec. 2025.
CSWYY'
s Cash-to-Debt Range Over the Past 10 Years
Min: 9.75 Med: 152.32 Max: No Debt
Current: 22.59
During the past 13 years, China Shineway Pharmaceutical Group's highest Cash to Debt Ratio was No Debt. The lowest was 9.75. And the median was 152.32.
CSWYY's Cash-to-Debt is ranked better than 81.89% of 983
companies
in the Drug Manufacturers industry
Industry Median: 0.98
vs CSWYY: 22.59
China Shineway Pharmaceutical Group (OTCPK:CSWYY) Cash-to-Debt Explanation
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
China Shineway Pharmaceutical Group Cash-to-Debt Related Terms
China Shineway Pharmaceutical Group Cash-to-Debt Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
China Shineway Pharmaceutical Group Cash-to-Debt Chart
For the Drug Manufacturers - Specialty & Generic subindustry, China Shineway Pharmaceutical Group's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
China Shineway Pharmaceutical Group Cash-to-Debt vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, China Shineway Pharmaceutical Group's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where China Shineway Pharmaceutical Group's Cash-to-Debt falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
China Shineway Pharmaceutical Group (CSWYY) has a Cash-to-Debt of 22.59 as of Dec. 2025. This is 85% below median its historical median of 152.32. Over the past decade, China Shineway Pharmaceutical Group's Cash-to-Debt has ranged from 9.75 to 10,000.00. According to the industry distribution chart, China Shineway Pharmaceutical Group ranks #178 out of 983 companies in the Drug Manufacturers industry, placing it in the top 18.1%.
Is China Shineway Pharmaceutical Group's Cash-to-Debt too high?
China Shineway Pharmaceutical Group's current Cash-to-Debt of 22.59 is 85% below median its 10-year median of 152.32. Over the past 10 years, this metric has ranged from a low of 9.75 to a high of 10,000.00. The Drug Manufacturers industry median Cash-to-Debt is 0.98. China Shineway Pharmaceutical Group's value of 22.59 is 2205.1% above this industry median. Based on the distribution chart, China Shineway Pharmaceutical Group ranks #178 out of 983 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, China Shineway Pharmaceutical Group has a GF Score™ of 87/100, reflecting its overall financial health beyond just this single metric.
How does China Shineway Pharmaceutical Group's Cash-to-Debt compare to ZTS?
According to the Drug Manufacturers industry distribution chart, China Shineway Pharmaceutical Group ranks #178 out of 983 companies for Cash-to-Debt. This places China Shineway Pharmaceutical Group in the top 18% of its industry — outperforming the majority of peers. The industry median Cash-to-Debt is 0.98. China Shineway Pharmaceutical Group's value of 22.59 is 2205.1% above this benchmark. Historically, China Shineway Pharmaceutical Group's own Cash-to-Debt has ranged from 9.75 to 10,000.00 over the past decade. While the company's 10-year median is 152.32 vs. the industry median of 0.98, China Shineway Pharmaceutical Group has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Drug Manufacturers company?
The median Cash-to-Debt among Drug Manufacturers companies is 0.98, based on 983 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. China Shineway Pharmaceutical Group's current Cash-to-Debt of 22.59 is 2205.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median Cash-to-Debt is 0.98 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. China Shineway Pharmaceutical Group's current Cash-to-Debt is 22.59, which is 85% below median its own 10-year median of 152.32. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is China Shineway Pharmaceutical Group stock overvalued right now?
China Shineway Pharmaceutical Group (CSWYY) has a current Cash-to-Debt of 22.59. The stock's GF Value™ is $16.01, compared to a current price of $19.25 — trading 20.2% above its estimated fair value. The current Cash-to-Debt is 22.59, which is 85% below median its 10-year median of 152.32 and 2205.1% above the Drug Manufacturers industry median of 0.98. China Shineway Pharmaceutical Group's overall GF Score™ is 87/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For China Shineway Pharmaceutical Group (CSWYY), the current Cash-to-Debt is 22.59 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is China Shineway Pharmaceutical Group (CSWYY) Overvalued in 2026?
Based on GuruFocus' analysis, China Shineway Pharmaceutical Group stock appears to be overvalued.
The current stock price of $19.25 is trading 20.2% above its estimated GF Value™ of $16.01.
Key valuation signals for CSWYY:
Cash-to-Debt: 22.59 (85% below median its 10-year median of 152.32)
GF Value™: $16.01 vs. price of $19.25 (20.2% above fair value)
Industry Position: 2205.1% above the Drug Manufacturers median (#178 of 983)
No single metric tells the full story. See the CSWYY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
China Shineway Pharmaceutical Group Ltd is an investment holding company. Along with its subsidiaries, it is engaged in the research, development, manufacturing, and trading of modern Chinese medicines. The company's products comprise injection, soft capsule, granule, traditional Chinese medicine formula granules, and others, of which injections generate maximum revenue for the company. Geographically, the group operates in the People's Republic of China (PRC) and Hong Kong.
87GF Score
Get the complete analysis for CSWYY
Cash-to-Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CSWYY has been successfully added to your 
